Pharma Company Achieves 4x Faster Target Identification for Inflammatory Disease

Key Highlights

  • A pharmaceutical company based in Boston aimed to speed up their target discovery and validation process for inflammatory disease using single-cell RNA-seq data.
  • Elucidata systematically addressed this challenge by leveraging curated data on Polly and their expertise in analyzing single-cell RNA-seq data.
  • This resulted in the identification of four new targets and the validation of five pre-identified targets.
  • The pharma achieved a four-fold acceleration in target identification and validation with the help of this partnership.

All Case Studies

Request Demo